The problem of treating influenza and acute respiratory infections in pregnant and breastfeeding women remains an urgent issue of global public health. Pregnant women belong to a high-risk group for respiratory infections due to hormonal and physiological changes occurring during gestation, which predispose them to a severe and complicated course of disease, especially in the third trimester of pregnancy. The limited number of medicinal products that are both effective and approved for use during pregnancy highlights the need to develop and implement new approaches to the prevention and treatment of acute respiratory viral infections (ARVI) in pregnant women.

At present, one of the most promising directions is the use of drugs with antiviral properties that also enhance immune system function, thereby preventing complications and reducing reproductive losses.

: Acute respiratory infections, pregnancy, breastfeeding women

Timchenko V.N., Sukhovetskaya V.F., Chernova T.M., Barakina E.V., Pochinyaeva L.M., Malinovskaya V.V., Semenenko T.A., Shuvalov A.N. The role of early etiological identification of acute respiratory viral infections in the choice of antiviral therapy in hospitalized children. Pediatrics. Journal named after G.N. Speransky. 2020;99(1):100–106. (In Russ.) DOI: 10.24110/0031-403X-2020-99-1-100-106.

Guidelines. Influenza and other acute respiratory infections during the ongoing COVID-19 pandemic: prevention and treatment. Moscow; 2022. (In Russ.)

Semenenko T.A., Akimkin V.G., Burtseva E.I., Nozdracheva A.V., Simonova E.G., Tutelyan A.V., et al.

Characteristics of the epidemic situation associated with acute respiratory viral infections during the COVID-19 pandemic. Epidemiology and Vaccinal Prevention. 2022;21(4):4–15. (In Russ.)

DOI: 10.31631/2073-3046-2022-21-4-4-15.

Guidelines. Influenza and acute respiratory viral infections: modern etiotropic and pathogenetic therapy. Algorithms for medical care. Moscow; 2019. (In Russ.)

Sokolov D.I., Stepanova O.I., Selkov S.A.

The role of different CD4+ T-lymphocyte subpopulations during pregnancy. Medical Immunology (Russia). 2016;18(6):521–536. (In Russ.) DOI: 10.15789/1563-0625-2016-6-521-536.

Kostinov M.P., Khromova E.A., Savisko A.A., Kostinova A.M. Functional features of the immune system during physiological pregnancy and their relationship with influenza vaccination. Consilium Medicum. 2016;18(6):59–62. (In Russ.)

Abdullahi H., Elnahas A., Konje J.C. Seasonal influenza during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021;258:235–239. DOI: 10.1016/j.ejogrb.2021.01.005.

Fuhler G.M. The immune system and microbiome in pregnancy. Best Practice & Research Clinical Gastroenterology. 2020;44–45:101671. DOI: 10.1016/j.bpg.2020.101671.

Zapolskikh A.M., Lytkina I.N., Mikheeva I.V., Malyshev N.A., Bazarova M.V., Serobyan A.G. Clinical and epidemiological characteristics of influenza A(H1N1) in pregnant women. Epidemiology and Vaccinal Prevention. 2014;1(74):66–73. (In Russ.)

Avdeeva M.G., Gafurova O.R. Highly pathogenic influenza A(H1N1) in pregnant women and its impact on pregnancy outcomes. 2018;23(3):119–125. (In Russ.) DOI: 10.18821/1560-9529-2018-23-3-119-125.

Nozdracheva A.V., Gotvyanskaya T.P., Semenenko A.V., Afonin S.A. Main directions of nonspecific prevention of infectious diseases. Sanitary Doctor. 2021;11:24–37. (In Russ.) DOI: 10.33920/med-08-2111-02.

Selkova E.P., Yakovlev V.N., Semenenko T.A., Filatov N.N., Gotvyanskaya T.P., Danilina G.A., et al. Evaluation of amixin efficacy in the prevention of acute respiratory viral infections. Journal of Microbiology, Epidemiology and Immunobiology. 2001;3:42–46. (In Russ.)

Romantsov M.G., Selkova E.P., Garashchenko M.V., Semenenko T.A., Shuldyakov A.A., Kondratieva E.I., et al. Enhancement of natural resistance in children for influenza and ARVI prevention: results of multicenter randomized trials. Antibiotics and Chemotherapy. 2009;54(9–10):37–41. (In Russ.)

Khaitov R.M., Ataullakhanov R.I., Shulzhenko A.E., editors. Immunotherapy: Guidelines for Physicians. Moscow: GEOTAR-Media; 2020. 702 p. (In Russ.)

Kuklina L.V., Kravchenko E.N., Ozherelyeva M.A., Zadorozhnaya E.A., Vyzhlova E.N., Baranov I.I.

Risk factors for acute respiratory viral infections in pregnant women and effectiveness of preventive measures. Gynecology, Obstetrics and Perinatology. 2021;20(3):85–91. (In Russ.) DOI: 10.20953/1726-1678-2021-3-85-91.

Nesterova I.V., Kovaleva S.V., Chudilova G.A., et al. Efficacy and safety of Viferon in mono- and combined immunotherapy of immunocompromised children with recurrent respiratory infections. Pharmateca. 2017;4(337):54–62. (In Russ.)

Malinovskaya V.V., Baranov I.I., Vyzhlova E.N., Shuvalov A.N. Treatment of acute respiratory infections in pregnant women. Obstetrics and Gynecology: News, Opinions, Training. 2019;4(7):72–78. (In Russ.) DOI: 10.24411/2303-9698-2019-14006.

Ruzhentsova T.A., Khavkina D.A., Chukhlyaev P.V., Shushakova E.K. Efficacy and safety of interferon alfa-2b with vitamins C and E for treatment and prevention of congenital pneumonia. Medical Alphabet. 2020;18:61–66. (In Russ.) DOI: 10.33667/2078-5631-2020-18-61-66.

Belokrinitskaya T.E., Liga V.F., Trubitsyna A.Yu., Tarbaeva D.A. Drug-based prevention of influenza in pregnant women. Gynecology, Obstetrics and Perinatology. 2012;11(4):31–36. (In Russ.)

Bocharova I.I., Zarochentseva N.V., Aksenov A.N., Malinovskaya V.V., Vyzhlova E.N., Semenenko T.A., et al. Prevention of acute respiratory viral infections in newborns and their mothers during the COVID-19 pandemic. Gynecology, Obstetrics and Perinatology. 2021;20(2):66–74. (In Russ.)

DOI: 10.20953/1726-1678-2021-2-66-74.

Gabdullina R.Z. Treatment and prevention of influenza A/H1N1 in pregnant women. Bulletin of Feron. 2012;2:26–34. (In Russ.)

Kostinov M.P., Meshcheryakova A.K., Kytko O.V., Malinovskaya V.V., et al. Clinical effects of VIFERON® in pregnant women with acute respiratory infection. Chief Physician of the South of Russia. 2014;1(38):43. (In Russ.)

Martynova G.P., Ikkes L.A., Bogvilene Y.A. Clinical efficacy of combined use of two dosage forms of recombinant interferon alfa-2b in children with infectious mononucleosis. Childhood Infections. 2019;18(1):42–47. (In Russ.) DOI: 10.22627/2072-8107-2019-18-1-42-47.

Kravchenko E.N., Kuklina L.V., Ovchinnikova E.M., Chebakova V.Yu., et al. COVID-19 in pregnancy: clinical course and rational therapy using recombinant interferon alfa-2b. Russian Bulletin of Obstetrician-Gynecologist. 2021;21(5):96–101. (In Russ.) DOI: 10.17116/rosakush20212105196.